| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STK17A |
| Uniprot No | Q9UEE5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 64-321aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSGRELGRG KFAVVRKCIK KDSGKEFAAK FMRKRRKGQD CRMEIIHEIA VLELAQDNPW VINLHEVYET ASEMILVLEY AAGGEIFDQC VADREEAFKE KDVQRLMRQI LEGVHFLHTR DVVHLDLKPQ NILLTSESPL GDIKIVDFGL SRILKNSEEL REIMGTPEYV APEILSYDPI SMATDMWSIG VLTYVMLTGI SPFLGNDKQE TFLNISQMNL SYSEEEFDVL SESAVDFIRT LLVKKPEDRA TAEECLKHPW L |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STK17A重组蛋白的虚构参考文献示例(仅供参考，实际文献需通过学术数据库验证)：
---
1. **文献名称**: *"Recombinant STK17A induces apoptosis through caspase-3 activation in human cancer cells"*
**作者**: Yamamoto, K., et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组STK17A蛋白，证实其通过磷酸化下游靶点激活caspase-3通路，促进肿瘤细胞凋亡，提示其在癌症治疗中的潜在应用。
2. **文献名称**: *"Structural and functional characterization of the kinase domain of STK17A"*
**作者**: Chen, L., et al.
**摘要**: 通过昆虫细胞系统表达重组STK17A激酶结构域，结合X射线晶体学解析其三维结构，揭示ATP结合口袋的关键残基，为设计特异性抑制剂奠定基础。
3. **文献名称**: *"STK17A regulates DNA damage response via phosphorylation of H2AX"*
**作者**: Johnson, R.B., et al.
**摘要**: 利用哺乳动物细胞表达的重组STK17A蛋白，证明其直接磷酸化H2AX(Ser139)，参与DNA损伤修复调控，缺失STK17A导致基因组不稳定性增加。
4. **文献名称**: *"Development of a high-throughput assay for STK17A kinase activity screening"*
**作者**: Smith, T., et al.
**摘要**: 报道了一种基于重组STK17A蛋白的体外激酶活性检测方法，用于筛选小分子抑制剂，并鉴定出多个具有潜在治疗价值的化合物。
---
**注意**：以上内容为示例性模拟，实际文献需通过PubMed、Web of Science等平台检索。建议使用关键词“STK17A recombinant”“serine/threonine kinase 17A expression”等进行精准查询。
STK17A (serine/threonine kinase 17A), also known as DRAK1 (DAP kinase-related apoptosis-inducing protein kinase 1), is a member of the death-associated protein (DAP) kinase family. It encodes a calcium/calmodulin-regulated serine/threonine kinase implicated in apoptosis, DNA damage response, and cellular stress pathways. The protein contains a conserved kinase domain and a nuclear localization signal, enabling its role in regulating nuclear processes. STK17A is activated by pro-apoptotic stimuli and contributes to programmed cell death through phosphorylation of downstream targets, potentially interacting with p53 and other tumor suppressors.
Recombinant STK17A protein is engineered for in vitro studies to elucidate its biochemical properties, substrate specificity, and functional mechanisms. Produced via heterologous expression systems (e.g., E. coli, mammalian cells), the purified protein retains kinase activity and structural integrity, enabling researchers to investigate its role in cancer progression, neurodegenerative diseases, and oxidative stress responses. Studies suggest STK17A is upregulated in certain cancers (e.g., pancreatic, hepatocellular carcinoma) and may promote metastasis, making it a potential therapeutic target. Conversely, its dysregulation is linked to impaired apoptosis in chemotherapy resistance.
The recombinant protein facilitates kinase activity assays, inhibitor screening, and structural studies (e.g., crystallography). Its application extends to exploring interactions with binding partners, such as transcription factors or DNA repair proteins, shedding light on crosstalk between apoptotic signaling and genomic stability. Recent work also implicates STK17A in autoimmune disorders, highlighting its multifaceted roles. Availability of recombinant STK17A accelerates preclinical research, offering tools to develop targeted therapies modulating its activity in disease contexts.
×
